This trial is a Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding. Avatrombopag is designed to trigger the body to make more platelets.


Active, but not recruiting